IPZYF yields 248.29% · JNJ yields 2.14%● Live data
📍 IPZYF pulled ahead of the other in Year 1
Combined, IPZYF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IPZYF + JNJ for your $10,000?
IP Group Plc is a private equity and venture capital firm specializing in seed, early stage, start-up, incubation, growth capital, and mature financing. The firm also provides seed capital financing to spin out companies from the universities. It seeks to invest in the life sciences, physical sciences, energy & renewables, medical equipment and supplies, healthcare, technology, cleantech, intellectual property, pharmaceuticals & biotechnology, information technology & communications, and chemicals & materials. It also provides support for its university partners' intellectual property commercialization activities, as well as in the identification of intellectual property. It typically invests between £0.5 million ($0.75 million) and £1 million ($1.50 million) per investment. The firm prefers to takes equity positions in its portfolio companies. IP Group Plc was founded in 2001 and is based in London, United Kingdom with additional offices in Wilmington, Delaware; Hong Kong S.A.R., Hong Kong and Melbourne, Australia.
Full IPZYF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.